Glioma clinical trials in Pennsylvania
18 studies for Glioma are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07326566ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Children's Hospital of Philidelphia, Philidelphia
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated Oct 23, 2026 · NCT06838676SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Thomas Jefferson University Hospital, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT05303519A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
- The Children s Hospital of Philadelphia, Philadelphia
RecruitingEarly phase 1
Ages 1 to 21 · All sexes · Updated Sep 22, 2026 · NCT05555550Targeted Pediatric High-Grade Glioma Therapy
- Children's Hospital of Philadelphia, Philadelphia
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Study of Olutasidenib and Temozolomide in HGG
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
Ages 3 to 39 · All sexes · Updated Aug 24, 2026 · NCT05096481Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 1
Ages 1 to 25 · All sexes · Updated Aug 18, 2026 · NCT04485559A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Thomas Jefferson University, Philadelphia
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
- Lehigh Valley Health Network (Data Collection Only), Allentown
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT05188508Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 1/2
Ages 4 to 39 · All sexes · Updated Jul 20, 2026 · NCT05278208Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Children's Hospital of Philadelphia, Philadelphia
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 20, 2026 · NCT06326411A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Children's Hospital of Philadelphia, Philadelphia
RecruitingEarly phase 1
Up to age 21 · All sexes · Updated Mar 18, 2026 · NCT04655404All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
- University of Pennsylvania, Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 20, 2026 · NCT0534500218F-Fluciclovine PET-MRI in High-grade Glioma
- Children's Hospital of Philadelphia, Philadelphia
RecruitingEarly phase 1
Ages 1 to 21 · All sexes · Updated Dec 4, 2025 · NCT05553041From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.